表 2.
类癌相关免疫治疗临床试验及回顾性研究
ICIs related clinical trials and retrospective study of immunotherapy for carcinoid
| Research | Phase | n | Drugs | ORR | mPFS (mon) | mOS (mon) | Identifier |
| spa: Spartalizumab; AC: atypical carcinoid. | |||||||
| KEYNOTE-028[35] | Ib | 107 | pem | 12.0% | 5.6 | 21.1 | NCT02054806 |
| Janice et al[36] | Retrospective | 25 | pem | 12.0% | 5.6 | ||
| Yao et al[38] | II | 30 | spa | 16.7% | NCT02955069 | ||
| CA209-538[39] | II | 29 | ipi+nivo | 24.0% (AC: 33.0%) | 4.8 | 14.8 | NCT02923934 |